The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

Also called NCT04654390

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04654390
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04654390. Randomized; double masking; primary purpose treatment. Start 2020-12-30 (actual); primary completion 2021-12-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
DWP16001 Amg
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct04654390
Content hash
b78a82cbd7b07907151e7df083fc2d6aa8503044b0672f33ba3f54ab105d772e